JHEP Reports
Издатель: Elsevier · ISSN 2589-5559 · 80 статей
- Machine learning–guided personalized immunochemotherapy strategies in intrahepatic cholangiocarcinoma
- A dynamic prognostic and adaptive treatment framework for advanced biliary tract cancer
- Real-world data from patients treated with chemotherapy for biliary tract cancer: Insights from a prognostic model
- Time-restricted eating, liver health, and fecal microbiota in adults with overweight or obesity: A randomized controlled trial
- EQ-5D health utility gains with once-weekly semaglutide 2.4 mg in people with MASH and F2/F3 fibrosis: An analysis of ESSENCE
- Peripartum ALT flares predict earlier postpartum HBeAg clearance in highly viremic HBV-infected women: A long-term follow-up study
- The use of FGF21 analogues in MASH and MASH cirrhosis – metabolic master regulators or liver-specific mechanisms?
- Anxiety and depression in liver disease: Pathways, prevalence, and implications for care
- Copyright and information
- Integrating patient advocacy into hepatology practice - Current perspective and future directions
- New CLA3+/4 scores predict outcomes in MASLD
- Single-cell profiling reveals monocyte mitochondrial dysfunction in patients with cirrhosis progressing to acute-on-chronic liver failure
- A novel preclinical platform to study FGFR2 fusion-driven cholangiocarcinoma☆
- Porto-sinusoidal vascular disorder-type lesions in patients with early fibrotic stages of metabolic dysfunction-associated steatotic liver disease
- Precision medicine in patients with advanced biliary tract cancer
- Patient Awareness and Disease Burden in MASLD: A Large-Scale Survey
- Effect of two TM6SF2 variants on steatotic liver disease, cirrhosis, and hepatocellular carcinoma
- Age-specific histological features of severe alpha-1 antitrypsin deficiency-associated liver disease (Pi*ZZ genotype) ☆
- Skeletal Muscle Loss with Atezolizumab-Bevacizumab versus Lenvatinib in Unresectable HCC
- Editorial - We all agree – adjuvant capecitabine is not good enough in BTC
- Before we redraw the line: Caution on steatosis-adjusted cT1 cut-offs for predicting mortality
- Medical therapy of MASLD – consequences of the paradigm shift from histology to non-invasive tests
- Hyperinflammatory reprogramming marks the transition from MASH to HCC
- Aligned ELF and VCTE cut-offs facilitate risk staging in patients with metabolic dysfunction-associated steatohepatitis
- High HBV antigen levels drive loss of vaccine-induced CD8+ T-cell function in carrier mice over time
- Hepatitis C RNA prevalence before and during broad access to direct-acting antivirals in people with HIV across six countries
- Seladelpar improves liver stiffness in PBC: ASSURE interim analysis
- Prevalence and significance of combined low muscle volume and high muscle fat in patients with Child-Pugh A-B cirrhosis
- Magnitude of portal pressure reduction and clinical outcomes in randomized trials
- Intestinal barrier dysfunction assessed by confocal laser endomicroscopy correlates with cirrhosis severity and clinical outcomes